Hester Biosciences Q1 FY27: Standalone Revenue Up 14%, Consolidated Profit Up 459%

Hester Biosciences Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Standalone revenue saw a 14% increase to ₹726.60 million, with profit after tax (PAT) rising by 88% to ₹147.11 million. This growth was driven by a strong performance in the Poultry Healthcare Division, which increased revenues by 48%, and improved gross profit margins to 78%. Consolidated revenues, however, decreased by 8% to ₹841.05 million, primarily due to lower revenues from Nepal and Africa operations. Despite the revenue dip, consolidated PAT surged by 459% to ₹967.32 million, largely influenced by an exceptional gain of ₹853.49 million from the amendment of a Gates Foundation loan at Hester Africa. The company remains focused on strengthening its biologicals portfolio and expanding market penetration.